National Health Investors Earnings Call Transcripts
Fiscal Year 2026
-
The meeting highlighted strong 2025 financial results, including double-digit growth in NFFO and FAD per share, a raised dividend, and a strategic shift toward private pay senior housing. All directors were re-elected, executive compensation was approved, and BDO was ratified as auditor.
-
Q1 2026 results exceeded expectations with strong SHOP growth and a $560M NHC portfolio sale advancing capital recycling. Updated guidance reflects near-term earnings pressure but positions for long-term growth, with robust liquidity and a focus on private pay senior housing.
Fiscal Year 2025
-
Normalized FFO per share grew 8.9% in Q4 and 10.6% for the year, driven by strong SHOP performance and record investments. 2026 guidance projects modest FFO growth due to non-recurring 2025 items and planned asset dispositions, with SHOP expected to drive future NOI growth.
-
Third quarter results exceeded expectations with strong SHOP NOI growth, raised guidance, and robust investment activity. Liquidity and leverage remain favorable, while legal and competitive risks are being actively managed.
-
Second quarter results surpassed expectations, with strong SHOP NOI growth and raised 2025 guidance. Liquidity and balance sheet remain robust, supporting accelerated acquisitions and a dividend increase. SHOP transitions and strategic hires position the company for continued growth.
-
Q1 2025 results exceeded expectations with strong acquisition activity, higher rent collections, and raised guidance for FFO and FAD. SHOP segment showed NOI growth and improved occupancy, while the balance sheet remains strong and the investment pipeline robust.
Fiscal Year 2024
-
Fourth quarter and full-year 2024 results exceeded expectations, with strong growth in SHOP NOI, FFO, and FAD. 2025 guidance anticipates continued growth, $225 million in new investments, and further SHOP expansion, while maintaining a strong balance sheet and monitoring risks related to operator transitions and federal policy.
-
Q3 2024 saw strong portfolio fundamentals, with sequential improvements in occupancy and EBITDA coverage, robust investment activity, and a tightened SHOP NOI growth outlook. Net income and FFO per share declined year-over-year, but FAD and SHOP NOI posted solid gains.
-
Q2 2024 results exceeded expectations with strong FFO and FAD growth, robust SHOP performance, and a raised 2024 outlook. Investment activity and pipeline are accelerating, supported by a solid balance sheet and favorable market trends.